DA-E 5090 is deacetylated form of E5090, is pharmacologically active metabolite of E 5090, is interleukin-1 antagonist. DA-E 5090 is a novel inhibitor of IL-1 generation, in vitro inhibitory effects on the generation of IL-1 by human monocytes. E5090 is an orally bioavailable inhibitor of IL-1 generation, being converted in vivo into the pharmacologically active deacetylated form (DA-E5090). In vitro effects of DA-E5090 on the generation of IL-1 by human monocytes stimulated with LPS were examined. DA-E5090 inhibited both IL-1 alpha and IL-1 beta generation by human monocytes stimulated with 1 microgram/ml of LPS in a dose dependent-manner (1-10 microM), as determined by LAF assay and ELISA. Northern blotting analysis indicated that DA-E5090 inhibits transcription of IL-1 alpha and IL-1 beta m-RNAs. References: Tanaka M, Chiba K, Okita M, Kaneko T, Tagami K, Hibi S, Okamoto Y, Shirota H, Goto M, Sakurai H, et al. 3-(5-Alkyl-4-hydroxy-3-methoxy-1-naphthalenyl)-2-methyl-2-propenoic acids as orally active inhibitors of IL-1 generation. J Med Chem. 1991 Aug;34(8):2647-9. PubMed PMID: 1875355.

纯度：≥98%

CAS：131420-84-3